Reviva Pharmaceuticals Holdings Inc. (RVPH) continues to draw attention as a late-stage biopharmaceutical company advancing next-generation therapeutics for diseases with significant unmet medical needs.
The company's pipeline is centered on central nervous system (CNS), inflammatory, and cardiometabolic conditions, with two in-house discovered drug candidates: brilaroxazine (RP5063) and RP1208. Both compounds are protected by composition of matter patents in the United States, Europe, and several other countries.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com